Articles

SATB2 promotes EMT-like, invasive, and endothelial tube-promoting phenotypes with the involvement of ZEB1 in 8305C anaplastic thyroid cancer cells

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 4 November 2026
23
Views
12
Downloads

Authors

Anaplastic thyroid cancer (ATC) exhibits marked dedifferentiation, rapid invasion, and limited therapeutic responsiveness. This study investigated associations between SATB2, ZEB1, EMT-like changes, invasion, short-term vemurafenib response, and endothelial tube-promoting activity in 8305C cells as an in vitro proof-of-concept model. SATB2 was overexpressed or silenced, followed by reciprocal ZEB1 manipulation to assess its contribution to SATB2-associated phenotypes. Expression was assessed by quantitative real-time PCR, Western blotting, and immunofluorescence. ChIP-qPCR examined SATB2 enrichment at a selected ZEB1 promoter region. Transwell assays assessed invasion, and Western blotting evaluated EMT- and angiogenesis-associated proteins. Short-term vemurafenib responses were measured using CCK-8 concentration–response assays. Supernatant VEGFA concentrations were determined by ELISA, and conditioned media were tested in HUVEC tube-formation assays. SATB2 manipulation produced concordant changes in ZEB1 mRNA and protein expression. ChIP-qPCR demonstrated significant SATB2 enrichment at the examined ZEB1 promoter region relative to IgG, indicating association without establishing direct transcriptional activation. SATB2 overexpression increased invasion, decreased E-cadherin, and increased Vimentin, VEGFA, and PDGF-BB expression; silencing produced opposite changes. SATB2 overexpression shifted the short-term vemurafenib concentration-response curve toward a higher IC50, whereas silencing shifted it toward a lower IC50. Reciprocal ZEB1 manipulation attenuated molecular and functional changes associated with SATB2 gain- or loss-of-function, supporting ZEB1 involvement. Conditioned medium from SATB2-overexpressing cells promoted HUVEC tube formation, which was attenuated by ZEB1 silencing. In 8305C cells, SATB2 was associated with ZEB1 expression, EMT-like remodeling, invasion, altered short-term vemurafenib response, and endothelial tube-promoting activity. Reciprocal ZEB1 manipulation supports its involvement in these phenotypes, but ChIP-qPCR does not establish direct SATB2-mediated transcriptional activation of ZEB1. Findings are limited to a single ATC cell-line model and require validation in additional experimental models.

Downloads

Download data is not yet available.

Citations

1. Bible KC, Kebebew E, Brierley J, Brito JP, Cabanillas ME, Clark TJ, Jr. et al. 2021 American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid 2021;31:337-86. DOI: https://doi.org/10.1089/thy.2020.0944
2. Rao SN, Smallridge RC. Anaplastic thyroid cancer: An update. Best Pract Res Clin Endocrinol Metab 2023;37:101678. DOI: https://doi.org/10.1016/j.beem.2022.101678
3. Alobuia W, Gillis A, Kebebew E. Contemporary management of anaplastic thyroid cancer. Curr Treat Options Oncol 2020;21:78. DOI: https://doi.org/10.1007/s11864-020-00776-2
4. Dey T, Yadav BS. Anaplastic thyroid cancer: Unveiling advances in diagnosis and management. World J Clin Oncol 2024;15:786-9. DOI: https://doi.org/10.5306/wjco.v15.i7.786
5. Scheffel RS, Dora JM, Maia AL. BRAF mutations in thyroid cancer. Curr Opin Oncol 2022;34:9-18. DOI: https://doi.org/10.1097/CCO.0000000000000797
6. Schubert L, Mariko ML, Clerc J, Huillard O, Groussin L. MAPK pathway inhibitors in thyroid cancer: preclinical and clinical data. Cancers (Basel) 2023;15. DOI: https://doi.org/10.3390/cancers15030710
7. Basu A, Paul MK, Weiss S. The actin cytoskeleton: morphological changes in pre- and fully developed lung cancer. Biophys Rev (Melville) 2022;3:041304. DOI: https://doi.org/10.1063/5.0096188
8. Zhang YE, Stuelten CH. Alternative splicing in EMT and TGF-beta signaling during cancer progression. Semin Cancer Biol 2024;101:1-11. DOI: https://doi.org/10.1016/j.semcancer.2024.04.001
9. Park JH, Myung JK, Lee SJ, Kim H, Kim S, Lee SB, et al. ABCA1-mediated EMT Promotes papillary thyroid cancer malignancy through the ERK/Fra-1/ZEB1 pathway. Cells 2023;12. DOI: https://doi.org/10.3390/cells12020274
10. Guo L, Rao Y, Song Y, Hu J, Luo Z, Sun S, et al. SIX1 transmits signals for breast cancer progression via the ZEB1/IL6/STAT3 signaling axis. Oncogene 2025;44:3493-511. DOI: https://doi.org/10.1038/s41388-025-03499-6
11. Kowalczyk AE, Sliwinska-Jewsiewicka A, Krazinski BE, Piotrowska A, Grzegrzolka J, Godlewski J, et al. Reduced expression of SATB2 in colorectal cancer and its association with demographic and clinicopathological parameters. Int J Mol Sci 2025;26. DOI: https://doi.org/10.3390/ijms26052374
12. Gu W, Wang H, Huang X, Kraiczy J, Singh PNP, Ng C, et al. SATB2 preserves colon stem cell identity and mediates ileum-colon conversion via enhancer remodeling. Cell Stem Cell 2022;29:101-15 e10. DOI: https://doi.org/10.1016/j.stem.2021.09.004
13. Chen L, Xie X, Wang T, Xu L, Zhai Z, Wu H, et al. ARL13B promotes angiogenesis and glioma growth by activating VEGFA-VEGFR2 signaling. Neuro Oncol 2023;25:871-85. DOI: https://doi.org/10.1093/neuonc/noac245
14. Chen Q, Yu WY, Zhang HH, Zhang SZ, Fang J, Wu F, et al. PBX3 promotes tumor growth and angiogenesis via activation of AT1R/VEGFR2 pathway in papillary thyroid carcinoma. Biomed Res Int 2020;2020:8954513. DOI: https://doi.org/10.1155/2020/8954513
15. Shaha AR. Anaplastic thyroid cancer: shifting paradigms-A ray of hope. Thyroid 2023;33:402-3. DOI: https://doi.org/10.1089/thy.2023.29150.sha
16. Lu L, Wang JR, Henderson YC, Bai S, Yang J, Hu M, et al. Anaplastic transformation in thyroid cancer revealed by single-cell transcriptomics. J Clin Invest 2023;133:e169653. DOI: https://doi.org/10.1172/JCI169653
17. Liu W, Lin R, Zhu C, Chen Y, Gao Q, Zhong J. CCT2 regulates ZEB1-induced EMT gene transcription to promote the metastasis and tumorigenesis of papillary thyroid carcinoma. Discov Med 2024;36:1819-30. DOI: https://doi.org/10.24976/Discov.Med.202436188.168
18. Lu Y, Zhao Y, Liu P, Xu X. Vemurafenib activates the sonic hedgehog pathway and promotes thyroid cancer stem cell self-renewal. Endocr Relat Cancer 2023;30. DOI: https://doi.org/10.1530/ERC-22-0392
19. Zhao Y, Lu Y, Li W, Liu P, Xu X. Acquired resistance to vemurafenib restrains thyroid cancer stem cell self-renewal by suppressing STAT3 activation. Cell Signal 2025;133:111845. DOI: https://doi.org/10.1016/j.cellsig.2025.111845
20. Han PZ, Ye WD, Yu PC, Tan LC, Shi X, Chen XF, et al. A distinct tumor microenvironment makes anaplastic thyroid cancer more lethal but immunotherapy sensitive than papillary thyroid cancer. JCI Insight 2024;9:e173712. DOI: https://doi.org/10.1172/jci.insight.173712
21. Vosgha H, Ariana A, Smith RA, Lam AKY. miR-205 targets angiogenesis and EMT concurrently in anaplastic thyroid carcinoma. Endocr Relat Cancer 2018;25:323-37. DOI: https://doi.org/10.1530/ERC-17-0497

CRediT authorship contribution

Lixuan Wu, conceptualization, methodology, investigation, writing – original draft. Cong Wu, conceptualization, methodology, investigation, writing – original draft. Qin Liu, conceptualization, methodology, investigation, writing – original draft. Xuewen Liu, data curation. Xiaolong Wang, data curation. Lei Liu, formal analysis. Dexiang Li, formal analysis. All authors read and approved the final manuscript.

Data Availability Statement

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

How to Cite



1.
Wu L, Wu C, Liu X, Liu Q, Wang X, Liu L, et al. SATB2 promotes EMT-like, invasive, and endothelial tube-promoting phenotypes with the involvement of ZEB1 in 8305C anaplastic thyroid cancer cells. Eur J Histochem [Internet]. 2026 Nov. 4 [cited 2026 Nov. 6];70(4). Available from: https://www.ejh.it/ejh/article/view/4738